Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Multicenter, Parallel Group Study Evaluating the Efficacy and Safety of 135 μg and 90 μg of PEGASYS® Given as Monotherapy to Patients With Chronic Hepatitis C and End-Stage Renal Disease Undergoing Hemodialysis
Conditions
Interventions
Peginterferon alfa-2a
Locations
22
Austria
Graz, Austria
Vienna, Austria
Brasília, Brazil
Porto Alegre, Brazil
Sao Jose Rio Preto, Brazil
São Luís, Brazil
Start Date
June 1, 2004
Primary Completion Date
August 1, 2007
Completion Date
August 1, 2007
Last Updated
October 31, 2016
NCT05870969
NCT03987503
NCT04382404
NCT01226797
NCT00062816
NCT04774107
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions